The DermX^TM MegasphereTM Delivery System is a non-invasive, proprietary technology platform that enhances the rate and depth of penetration of various cosmetic actives and other ingredients through human skin. A liquid solution created by JRX Biotech (formerly ORYXE, INC.) in 1999 and protected by six U.S. patents, DermX^TM is a revolutionary transdermal system capable of delivering:

• Small and large molecules ("macro-molecules") up to 460,000 Daltons in size.
• Large volumes of actives (a "large payload") into the skin.
• Compounds deep into the dermis (the third layer of skin).
• Complete, intact molecules to the target zone.

Large Molecules: Traditional delivery system technologies can deliver only small molecules to the skin, thus severely limiting their efficacy, range, and flexibility. The DermX^TM MegasphereTM System, however, can deliver both small molecules (like peptides) and large molecules (like proteins). DermX^TM's unique value is its ability to deliver compounds that are potentially 10,000 times larger than those found in other non-invasive, passive systems. The breakthrough patented technology is the only known liquid-based system that allows such a wide range of actives (agents) to be absorbed through human skin.

Large Volumes: Unlike other technologies, DermX^TM has been proven to deliver large volumes (or a "large payload") of cosmetic actives into the skin. Currently, traditional technologies allow only 0.1 to 0.2% of an active to be absorbed. However, DermX^TM employs "megasphere technology", a mechanism that does not require a separate carrier and penetration enhancer. As a result, up to 2 to 4% of an active has been clinically proven to penetrate the skin, delivering 10 to 40 times more at one time than before. And by delivering more molecules at once, DermX^TM can provide the desired effect in half the time it takes other systems.

Deep Delivery: Human skin is made up of three main layers: the stratum corneum, the epidermis and the dermis. Traditional delivery system technologies can only deliver agents to the top layer, the stratum corneum. DermX^TM, however, has been proven to deliver these same agents deep into the third layer of skin. By allowing agents to penetrate deep into the dermis layer, DermX^TM increases the effectiveness of the employed actives and allows for a longer lasting desired effect.

Intact Delivery: Most traditional transdermal delivery systems (liposomes as an example) can deliver only small volumes of small molecules to the top layer of skin. The process is problematic as the delivered molecules frequently break down and denigrate as they attempt to cross the skin barrier. DermX^TM solves this dilemma by using megaspheres - a mechanism that encapsulates both the agent and carrier. Electrophoresis and immunoprecipitation studies have proven that once a molecule is absorbed through the skin using DermX^TM, this same active maintains its initial intact molecular structure. The DermX^TM technology represents the first liquid-based, "needle free", injection-less process for deep delivery of large molecular compounds.

DermX^TM has been clinically proven in a number of world renowned, independent laboratories using today's most sophisticated testing methods, including:

• The in vitro Franz Diffusion Cell test,
• Spectroscopy analysis,
• Electrophoresis, and
• Immunoprecipitation studies.

All Franz Diffusion Cell tests were conducted using human cadaver skin and 14C radiolabeled compounds, and were performed at the PRACS Institute, Ltd. - the recognized worldwide leader in dermatological and percutaneous (skin) absorption testing.